Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)

被引：0

作者：

Sehn, Laurie H. ^{[1
,2
]}

Luminari, Stefano ^{[3
,4
]}

Scholz, Christian W. ^{[5
]}

Huebel, Kai ^{[6
,7
,8
]}

Salar, Antonio ^{[9
]}

Paneesha, Shankara ^{[10
,11
]}

Wahlin, Bjorn E. ^{[12
]}

Panayiotidis, Panayiotis ^{[13
]}

Lee, Hui-Peng ^{[14
]}

Ubieto, Ana Jimenez ^{[15
]}

Sancho, Juan-Manuel ^{[16
]}

Kim, Tae Min ^{[17
]}

Domenech, Eva Domingo ^{[18
]}

Kumode, Takahiro ^{[19
]}

Poh, Christina ^{[20
]}

Thieblemont, Catherine ^{[21
]}

Deeren, Dries ^{[22
]}

de Wit, Edwin ^{[23
]}

Arbushites, Michael ^{[24
]}

Casadebaig, Marie-Laure ^{[23
]}

Trneny, Marek ^{[25
,26
]}

机构：

[1] BC Canc Ctr Lymphoid Canc, Vancouver, BC, Canada

[2] Univ British Columbia, Vancouver, BC, Canada

[3] Univ Modena & Reggio Emilia, Oncol & Regenerat Med, Surg Med & Dent Morphol Sci Related Transplant, Reggio Emilia, Italy

[4] Azienda USL IRCCS Reggio Emilia, Reggio Emilia, Italy

[5] Vivantes Klinikum Urban, Berlin, Germany

[6] Univ Cologne, Cologne, Germany

[7] Univ Hosp Cologne, Fac Med, Cologne, Germany

[8] Univ Hosp Cologne, Cologne, Germany

[9] Hosp Mar IMIM, Barcelona, Spain

[10] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, England

[11] Univ Birmingham, Birmingham, England

[12] Karolinska Univ Hosp, Stockholm, Sweden

[13] Natl & Kapodistrian Univ Athens, Gen Hosp LAIKO, Med Sch, Athens, Greece

[14] Flinders Med Ctr, Adelaide, Australia

[15] Hosp 12 Octubre, Serv Hematol, Madrid, Spain

[16] Univ Autonoma Bacrcelona, ICO IJC Hosp Germans Trias & Pujol, Barcelona, Spain

[17] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Seoul, South Korea

[18] Hosp Duran I Reynals, IDIBELL, Inst Catala Oncol, Barcelona, Spain

[19] Kindai Univ, Osaka, Japan

[20] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA USA

[21] St Paris Cite Univ, St Hosp, Assistance Publ Hop Paris, Paris, France

[22] AZ Delta Gen Hosp, Roeselare, Belgium

[23] Incyte Int Biosci, Sarl Morges, Switzerland

[24] Incyte Corp, Wilmington, DE USA

[25] Charles Univ Prague, Fac Med 1, Prague, Czech Republic

[26] Gen Hosp, Prague, Czech Republic

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-212970

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：LBA1 / LBA4

页数：4

共 50 条

[41] Updated interim analysis of the randomized phase 1b/3 study of tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma.
Batlevi, Connie Lee
Park, Steven I.
Phillips, Tycel Jovelle
Amengual, Jennifer
Andorsky, David Jacob
Campbell, Philip
Mckay, Pamela
Leonard, John Paul
Sondhi, Manu
Yang, Jay
Chen, Yingxue
O'Connor, Heather
Slatcher, Pamela
Morschhauser, Franck
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[42] Clinical Treatment Guidelines for Tafasitamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Nedved, Adrienne
Maddocks, Kami
Nowakowski, Grzegorz S.
ONCOLOGIST, 2023, : 199 - 207
[43] ANALYSIS OF A PHASE 2 STUDY OF LENALIDOMIDE AND RITUXIMAB IN RELAPSED OR REFRACTORY NON-HODGKIN'S LYMPHOMA
Dutia, M.
DeRoock, I.
Chee, K.
O'Donnell, R.
Quirch, C.
Reed-Pease, C.
Tuscano, J.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 118 - 118
[44] Phase 2 Study of Venetoclax Plus Rituximab or Randomized Ven Plus Bendamustine plus Rituximab (BR) Versus BR in Patients with Relapsed/Refractory Follicular Lymphoma: Interim Data
Zinzani, Pier Luigi
Topp, Max S.
Yuen, Sam L. S.
Rusconi, Chiara
Fleury, Isabelle
Pro, Barbara
Gritti, Giuseppe
Crump, Michael
Hsu, Wanling
Punnoose, Elizabeth A.
Hilger, James
Mobasher, Mehrdad
Hiddermann, Wolfgang
BLOOD, 2016, 128 (22)
[45] Epcoritamab SC With Rituximab plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma, Including Patients With POD24: Updated Results From EPCORE NHL-2
Merryman, Reid W.
Belada, David
Sureda, Anna
Leppa, Sirpa
Vermaat, Joost S. P.
Holte, Harald
Hutchings, Martin
Lugtenburg, Pieternella
de Vos, Sven
Abrisqueta, Pau
Nijland, Marcel
Christensen, Jacob Haaber
Wahlin, Bjorn E.
Linton, Kim M.
Wang Liwei
Abbas, Aqeel
Rana, Ali
Quadri, Syed
Falchi, Lorenzo
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S37 - S38
[46] A complete response to tafasitamab and lenalidomide in a patient with refractory grade 3B follicular lymphoma.
Germain, M.
Lampenfeld, J.
Safah, H.
Saba, N. S.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2023, 365 : S369 - S369
[47] CURRENT EPCORITAMAB PLUS RITUXIMAB AND LENALIDOMIDE (R2) PERCEPTIONS FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)
Levine, E.
Gentile, D.
Swain, R.
Bone, R. N.
Jennings-Zhang, L.
Jeune-Smith, Y.
Feinberg, B.
VALUE IN HEALTH, 2024, 27 (12) : S342 - S342
[48] A Phase Ib Study of Obinutuzumab Combined with Lenalidomide for Relapsed/Refractory Follicular B-Cell Lymphoma
Morschhauser, Franck
Salles, Gilles
Le Gouill, Steven
Tilly, Herve
Thieblemont, Catherine
Bouabdallah, Krimo
Cartron, Guillaume
Houot, Roch
BLOOD, 2014, 124 (21)
[49] Subcutaneous Epcoritamab With Rituximab plus Lenalidomide (R2) in Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Update from Phase 1/2 Trial
Falchi, Lorenzo
Leppa, Sirpa
Wahlin, Bjorn E.
Nijland, Marcel
Christensen, Jacob Haaber
De Vos, Sven
Holte, Harald
Linton, Kim M.
Abbas, Aqeel
Wang, Liwei
Dinh, Minh
Elliott, Brian
Belada, David
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S392 - S392
[50] A Phase II Study of Lenalidomide Plus Rituximab in Patients with Newly Diagnosed Follicular Lymphoma: An Interim Analysis
Zheng, Zhong
Wang, Li
Cheng, Shu
Xu, Pengpeng
Zhao, Weili
BLOOD, 2019, 134

← 1 2 3 4 5 →